Page last updated: 2024-08-21

isoxazoles and Metabolic Diseases

isoxazoles has been researched along with Metabolic Diseases in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Li, X; Li, Z; Lin, X; Luo, G; Xiang, H; Xiao, M; Zhang, D1
Dai, G; Zhang, Y1
Argo, TR; Bettinger, TL; Fowler, JA1

Reviews

1 review(s) available for isoxazoles and Metabolic Diseases

ArticleYear
Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Clinical therapeutics, 2008, Volume: 30, Issue:2

    Topics: Antipsychotic Agents; Delayed-Action Preparations; Dopamine Antagonists; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Humans; Isoxazoles; Metabolic Diseases; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Secondary Prevention; Serotonin Antagonists; Tablets; Treatment Outcome

2008

Trials

1 trial(s) available for isoxazoles and Metabolic Diseases

ArticleYear
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Human psychopharmacology, 2012, Volume: 27, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult

2012

Other Studies

1 other study(ies) available for isoxazoles and Metabolic Diseases

ArticleYear
Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    Topics: Administration, Oral; Animals; Benzothiazoles; Drug Evaluation, Preclinical; Gene Expression Regulation; Hep G2 Cells; Humans; Isoxazoles; Lipids; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Protein Binding; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship

2021